Tony Mattivi
Director

KANSAS BUREAU OF
INVESTIGATION
DEDICATION | SERVICE | INTEGRITY

Kris W. Kobach
Attorney General

Before the
House Health and Human Services Committee
Regarding HB 2765 (Proponent)
Bob Stuart, Executive Officer
February 12, 2026

Chairman Carpenter and members of the Committee:

Thank you for the opportunity to provide written proponent testimony on behalf of the Kansas Bureau of Investigation (KBI). The KBI supports House Bill 2765.

This legislation makes important updates to Kansas's Uniform Controlled Substances Act. These changes will enhance public safety, clarify existing law for law enforcement, and address emerging threats from dangerous synthetic and semi-synthetic substances.

Fentanyl-Related Changes

HB 2765 updates and clarifies the definition of a "fentanyl-related controlled substance" in K.S.A. 21-5701. It incorporates additional specific fentanyl analogs into the controlled substances schedules and refines the structural analog provisions.

Fentanyl and its analogs remain the leading cause of fatal overdoses in Kansas and across the nation. These updates close potential loopholes that clandestine manufacturers exploit when creating new variants. They provide KBI agents and local law enforcement with clearer tools to investigate, charge, and prosecute traffickers who distribute these deadly substances. This directly supports our efforts to disrupt supply chains and protect Kansas families.

THC Technical Language Update

The bill also includes technical clarifications to the language governing tetrahydrocannabinols (THC) and marijuana definitions. These adjustments don't change criminal law they just better align statutory language with current federal and state hemp regulations. This reduces ambiguity for both enforcement and regulated industries. This cleanup helps law enforcement focus resources on actual violations rather than interpretive gray areas.

Addition of 7-Hydroxymitragynine (7-OH) to Schedule I

Of particular importance to the KBI is the addition of 7-hydroxymitragynine (7-OH) to Schedule I. 7-OH is a potent opioid receptor agonist derived from the kratom plant but typically sold in highly

concentrated synthetic or semi-synthetic forms. These products far exceed the trace amounts found naturally in traditional kratom leaf.

These products are aggressively marketed and sold in gas stations, smoke shops, convenience stores, and online throughout Kansas. They often are sold in appealing formats such as gummies, shots, tablets, and powders. They are frequently promoted as "natural," safe, or legal alternatives for pain relief, anxiety, or opioid withdrawal. **In reality, concentrated 7-OH and related high-potency products act as powerful opioids.** They carry significant risks of:

- Rapid addiction and tolerance
- Respiratory depression
- Overdose (which can be reversed with naloxone but still endangers lives)
- Severe withdrawal symptoms
- Other adverse effects including anxiety, depression, and gastrointestinal distress

Recent federal seizures of tens of thousands of 7-OH products from Kansas City-area warehouses demonstrate the scale of distribution impacting our state. The Kansas Department of Health and Environment (KDHE) has already issued public warnings about these products. The KBI is seeing increasing encounters with these substances in investigations, often alongside other drugs. Young adults and unsuspecting consumers are particularly vulnerable due to easy access and misleading marketing.

Scheduling 7-OH in Kansas will give law enforcement the necessary authority to remove these dangerous products from the marketplace, prosecute illegal distribution, and deter manufacturers and retailers from endangering Kansans. It sends a clear message that Kansas will not tolerate the unchecked spread of potent opioid-like substances disguised as supplements or "wellness" products.

Conclusion

HB 2765 is a targeted, responsible update that modernizes our controlled substances laws to match current threats. The KBI appreciates the proactive work of the House Health and Human Services Committee and the bill's sponsors on these critical issues. We stand ready to assist with implementation and enforcement.

We respectfully request your favorable recommendation for passage of HB 2765.

#####

Tony Mattivi
Director

KANSAS BUREAU OF
INVESTIGATION
DEDICATION | SERVICE | INTEGRITY

Kris W. Kobach
Attorney General

Before the
House Health and Human Services Committee
Regarding HB 2765 (Proponent)
Bob Stuart, Executive Officer
February 12, 2026

Chairman Carpenter and members of the Committee:

Thank you for the opportunity to provide written proponent testimony on behalf of the Kansas Bureau of Investigation (KBI). The KBI supports House Bill 2765.

This legislation makes important updates to Kansas's Uniform Controlled Substances Act. These changes will enhance public safety, clarify existing law for law enforcement, and address emerging threats from dangerous synthetic and semi-synthetic substances.

Fentanyl-Related Changes

HB 2765 updates and clarifies the definition of a "fentanyl-related controlled substance" in K.S.A. 21-5701. It incorporates additional specific fentanyl analogs into the controlled substances schedules and refines the structural analog provisions.

Fentanyl and its analogs remain the leading cause of fatal overdoses in Kansas and across the nation. These updates close potential loopholes that clandestine manufacturers exploit when creating new variants. They provide KBI agents and local law enforcement with clearer tools to investigate, charge, and prosecute traffickers who distribute these deadly substances. This directly supports our efforts to disrupt supply chains and protect Kansas families.

THC Technical Language Update

The bill also includes technical clarifications to the language governing tetrahydrocannabinols (THC) and marijuana definitions. These adjustments don't change criminal law they just better align statutory language with current federal and state hemp regulations. This reduces ambiguity for both enforcement and regulated industries. This cleanup helps law enforcement focus resources on actual violations rather than interpretive gray areas.

Addition of 7-Hydroxymitragynine (7-OH) to Schedule I

Of particular importance to the KBI is the addition of 7-hydroxymitragynine (7-OH) to Schedule I. 7-OH is a potent opioid receptor agonist derived from the kratom plant but typically sold in highly

concentrated synthetic or semi-synthetic forms. These products far exceed the trace amounts found naturally in traditional kratom leaf.

These products are aggressively marketed and sold in gas stations, smoke shops, convenience stores, and online throughout Kansas. They often are sold in appealing formats such as gummies, shots, tablets, and powders. They are frequently promoted as "natural," safe, or legal alternatives for pain relief, anxiety, or opioid withdrawal. **In reality, concentrated 7-OH and related high-potency products act as powerful opioids.** They carry significant risks of:

- Rapid addiction and tolerance
- Respiratory depression
- Overdose (which can be reversed with naloxone but still endangers lives)
- Severe withdrawal symptoms
- Other adverse effects including anxiety, depression, and gastrointestinal distress

Recent federal seizures of tens of thousands of 7-OH products from Kansas City-area warehouses demonstrate the scale of distribution impacting our state. The Kansas Department of Health and Environment (KDHE) has already issued public warnings about these products. The KBI is seeing increasing encounters with these substances in investigations, often alongside other drugs. Young adults and unsuspecting consumers are particularly vulnerable due to easy access and misleading marketing.

Scheduling 7-OH in Kansas will give law enforcement the necessary authority to remove these dangerous products from the marketplace, prosecute illegal distribution, and deter manufacturers and retailers from endangering Kansans. It sends a clear message that Kansas will not tolerate the unchecked spread of potent opioid-like substances disguised as supplements or "wellness" products.

Conclusion

HB 2765 is a targeted, responsible update that modernizes our controlled substances laws to match current threats. The KBI appreciates the proactive work of the House Health and Human Services Committee and the bill's sponsors on these critical issues. We stand ready to assist with implementation and enforcement.

We respectfully request your favorable recommendation for passage of HB 2765.

#####

Tony Mattivi
Director

KANSAS BUREAU OF
INVESTIGATION
DEDICATION | SERVICE | INTEGRITY

Kris W. Kobach
Attorney General

Before the
House Health and Human Services Committee
Regarding HB 2765 (Proponent)
Bob Stuart, Executive Officer
February 12, 2026

Chairman Carpenter and members of the Committee:

Thank you for the opportunity to provide written proponent testimony on behalf of the Kansas Bureau of Investigation (KBI). The KBI supports House Bill 2765.

This legislation makes important updates to Kansas's Uniform Controlled Substances Act. These changes will enhance public safety, clarify existing law for law enforcement, and address emerging threats from dangerous synthetic and semi-synthetic substances.

Fentanyl-Related Changes

HB 2765 updates and clarifies the definition of a "fentanyl-related controlled substance" in K.S.A. 21-5701. It incorporates additional specific fentanyl analogs into the controlled substances schedules and refines the structural analog provisions.

Fentanyl and its analogs remain the leading cause of fatal overdoses in Kansas and across the nation. These updates close potential loopholes that clandestine manufacturers exploit when creating new variants. They provide KBI agents and local law enforcement with clearer tools to investigate, charge, and prosecute traffickers who distribute these deadly substances. This directly supports our efforts to disrupt supply chains and protect Kansas families.

THC Technical Language Update

The bill also includes technical clarifications to the language governing tetrahydrocannabinols (THC) and marijuana definitions. These adjustments don't change criminal law they just better align statutory language with current federal and state hemp regulations. This reduces ambiguity for both enforcement and regulated industries. This cleanup helps law enforcement focus resources on actual violations rather than interpretive gray areas.

Addition of 7-Hydroxymitragynine (7-OH) to Schedule I

Of particular importance to the KBI is the addition of 7-hydroxymitragynine (7-OH) to Schedule I. 7-OH is a potent opioid receptor agonist derived from the kratom plant but typically sold in highly

concentrated synthetic or semi-synthetic forms. These products far exceed the trace amounts found naturally in traditional kratom leaf.

These products are aggressively marketed and sold in gas stations, smoke shops, convenience stores, and online throughout Kansas. They often are sold in appealing formats such as gummies, shots, tablets, and powders. They are frequently promoted as "natural," safe, or legal alternatives for pain relief, anxiety, or opioid withdrawal. **In reality, concentrated 7-OH and related high-potency products act as powerful opioids.** They carry significant risks of:

- Rapid addiction and tolerance
- Respiratory depression
- Overdose (which can be reversed with naloxone but still endangers lives)
- Severe withdrawal symptoms
- Other adverse effects including anxiety, depression, and gastrointestinal distress

Recent federal seizures of tens of thousands of 7-OH products from Kansas City-area warehouses demonstrate the scale of distribution impacting our state. The Kansas Department of Health and Environment (KDHE) has already issued public warnings about these products. The KBI is seeing increasing encounters with these substances in investigations, often alongside other drugs. Young adults and unsuspecting consumers are particularly vulnerable due to easy access and misleading marketing.

Scheduling 7-OH in Kansas will give law enforcement the necessary authority to remove these dangerous products from the marketplace, prosecute illegal distribution, and deter manufacturers and retailers from endangering Kansans. It sends a clear message that Kansas will not tolerate the unchecked spread of potent opioid-like substances disguised as supplements or "wellness" products.

Conclusion

HB 2765 is a targeted, responsible update that modernizes our controlled substances laws to match current threats. The KBI appreciates the proactive work of the House Health and Human Services Committee and the bill's sponsors on these critical issues. We stand ready to assist with implementation and enforcement.

We respectfully request your favorable recommendation for passage of HB 2765.

#####

Tony Mattivi
Director

KANSAS BUREAU OF
INVESTIGATION
DEDICATION | SERVICE | INTEGRITY

Kris W. Kobach
Attorney General

Before the
House Health and Human Services Committee
Regarding HB 2765 (Proponent)
Bob Stuart, Executive Officer
February 12, 2026

Chairman Carpenter and members of the Committee:

Thank you for the opportunity to provide written proponent testimony on behalf of the Kansas Bureau of Investigation (KBI). The KBI supports House Bill 2765.

This legislation makes important updates to Kansas's Uniform Controlled Substances Act. These changes will enhance public safety, clarify existing law for law enforcement, and address emerging threats from dangerous synthetic and semi-synthetic substances.

Fentanyl-Related Changes

HB 2765 updates and clarifies the definition of a "fentanyl-related controlled substance" in K.S.A. 21-5701. It incorporates additional specific fentanyl analogs into the controlled substances schedules and refines the structural analog provisions.

Fentanyl and its analogs remain the leading cause of fatal overdoses in Kansas and across the nation. These updates close potential loopholes that clandestine manufacturers exploit when creating new variants. They provide KBI agents and local law enforcement with clearer tools to investigate, charge, and prosecute traffickers who distribute these deadly substances. This directly supports our efforts to disrupt supply chains and protect Kansas families.

THC Technical Language Update

The bill also includes technical clarifications to the language governing tetrahydrocannabinols (THC) and marijuana definitions. These adjustments don't change criminal law they just better align statutory language with current federal and state hemp regulations. This reduces ambiguity for both enforcement and regulated industries. This cleanup helps law enforcement focus resources on actual violations rather than interpretive gray areas.

Addition of 7-Hydroxymitragynine (7-OH) to Schedule I

Of particular importance to the KBI is the addition of 7-hydroxymitragynine (7-OH) to Schedule I. 7-OH is a potent opioid receptor agonist derived from the kratom plant but typically sold in highly

concentrated synthetic or semi-synthetic forms. These products far exceed the trace amounts found naturally in traditional kratom leaf.

These products are aggressively marketed and sold in gas stations, smoke shops, convenience stores, and online throughout Kansas. They often are sold in appealing formats such as gummies, shots, tablets, and powders. They are frequently promoted as "natural," safe, or legal alternatives for pain relief, anxiety, or opioid withdrawal. **In reality, concentrated 7-OH and related high-potency products act as powerful opioids.** They carry significant risks of:

- Rapid addiction and tolerance
- Respiratory depression
- Overdose (which can be reversed with naloxone but still endangers lives)
- Severe withdrawal symptoms
- Other adverse effects including anxiety, depression, and gastrointestinal distress

Recent federal seizures of tens of thousands of 7-OH products from Kansas City-area warehouses demonstrate the scale of distribution impacting our state. The Kansas Department of Health and Environment (KDHE) has already issued public warnings about these products. The KBI is seeing increasing encounters with these substances in investigations, often alongside other drugs. Young adults and unsuspecting consumers are particularly vulnerable due to easy access and misleading marketing.

Scheduling 7-OH in Kansas will give law enforcement the necessary authority to remove these dangerous products from the marketplace, prosecute illegal distribution, and deter manufacturers and retailers from endangering Kansans. It sends a clear message that Kansas will not tolerate the unchecked spread of potent opioid-like substances disguised as supplements or "wellness" products.

Conclusion

HB 2765 is a targeted, responsible update that modernizes our controlled substances laws to match current threats. The KBI appreciates the proactive work of the House Health and Human Services Committee and the bill's sponsors on these critical issues. We stand ready to assist with implementation and enforcement.

We respectfully request your favorable recommendation for passage of HB 2765.

#####

Tony Mattivi
Director

KANSAS BUREAU OF
INVESTIGATION
DEDICATION | SERVICE | INTEGRITY

Kris W. Kobach
Attorney General

Before the
House Health and Human Services Committee
Regarding HB 2765 (Proponent)
Bob Stuart, Executive Officer
February 12, 2026

Chairman Carpenter and members of the Committee:

Thank you for the opportunity to provide written proponent testimony on behalf of the Kansas Bureau of Investigation (KBI). The KBI supports House Bill 2765.

This legislation makes important updates to Kansas's Uniform Controlled Substances Act. These changes will enhance public safety, clarify existing law for law enforcement, and address emerging threats from dangerous synthetic and semi-synthetic substances.

Fentanyl-Related Changes

HB 2765 updates and clarifies the definition of a "fentanyl-related controlled substance" in K.S.A. 21-5701. It incorporates additional specific fentanyl analogs into the controlled substances schedules and refines the structural analog provisions.

Fentanyl and its analogs remain the leading cause of fatal overdoses in Kansas and across the nation. These updates close potential loopholes that clandestine manufacturers exploit when creating new variants. They provide KBI agents and local law enforcement with clearer tools to investigate, charge, and prosecute traffickers who distribute these deadly substances. This directly supports our efforts to disrupt supply chains and protect Kansas families.

THC Technical Language Update

The bill also includes technical clarifications to the language governing tetrahydrocannabinols (THC) and marijuana definitions. These adjustments don't change criminal law they just better align statutory language with current federal and state hemp regulations. This reduces ambiguity for both enforcement and regulated industries. This cleanup helps law enforcement focus resources on actual violations rather than interpretive gray areas.

Addition of 7-Hydroxymitragynine (7-OH) to Schedule I

Of particular importance to the KBI is the addition of 7-hydroxymitragynine (7-OH) to Schedule I. 7-OH is a potent opioid receptor agonist derived from the kratom plant but typically sold in highly

concentrated synthetic or semi-synthetic forms. These products far exceed the trace amounts found naturally in traditional kratom leaf.

These products are aggressively marketed and sold in gas stations, smoke shops, convenience stores, and online throughout Kansas. They often are sold in appealing formats such as gummies, shots, tablets, and powders. They are frequently promoted as "natural," safe, or legal alternatives for pain relief, anxiety, or opioid withdrawal. **In reality, concentrated 7-OH and related high-potency products act as powerful opioids.** They carry significant risks of:

- Rapid addiction and tolerance
- Respiratory depression
- Overdose (which can be reversed with naloxone but still endangers lives)
- Severe withdrawal symptoms
- Other adverse effects including anxiety, depression, and gastrointestinal distress

Recent federal seizures of tens of thousands of 7-OH products from Kansas City-area warehouses demonstrate the scale of distribution impacting our state. The Kansas Department of Health and Environment (KDHE) has already issued public warnings about these products. The KBI is seeing increasing encounters with these substances in investigations, often alongside other drugs. Young adults and unsuspecting consumers are particularly vulnerable due to easy access and misleading marketing.

Scheduling 7-OH in Kansas will give law enforcement the necessary authority to remove these dangerous products from the marketplace, prosecute illegal distribution, and deter manufacturers and retailers from endangering Kansans. It sends a clear message that Kansas will not tolerate the unchecked spread of potent opioid-like substances disguised as supplements or "wellness" products.

Conclusion

HB 2765 is a targeted, responsible update that modernizes our controlled substances laws to match current threats. The KBI appreciates the proactive work of the House Health and Human Services Committee and the bill's sponsors on these critical issues. We stand ready to assist with implementation and enforcement.

We respectfully request your favorable recommendation for passage of HB 2765.

#####

Tony Mattivi
Director

KANSAS BUREAU OF
INVESTIGATION
DEDICATION | SERVICE | INTEGRITY

Kris W. Kobach
Attorney General

Before the
House Health and Human Services Committee
Regarding HB 2765 (Proponent)
Bob Stuart, Executive Officer
February 12, 2026

Chairman Carpenter and members of the Committee:

Thank you for the opportunity to provide written proponent testimony on behalf of the Kansas Bureau of Investigation (KBI). The KBI supports House Bill 2765.

This legislation makes important updates to Kansas's Uniform Controlled Substances Act. These changes will enhance public safety, clarify existing law for law enforcement, and address emerging threats from dangerous synthetic and semi-synthetic substances.

Fentanyl-Related Changes

HB 2765 updates and clarifies the definition of a "fentanyl-related controlled substance" in K.S.A. 21-5701. It incorporates additional specific fentanyl analogs into the controlled substances schedules and refines the structural analog provisions.

Fentanyl and its analogs remain the leading cause of fatal overdoses in Kansas and across the nation. These updates close potential loopholes that clandestine manufacturers exploit when creating new variants. They provide KBI agents and local law enforcement with clearer tools to investigate, charge, and prosecute traffickers who distribute these deadly substances. This directly supports our efforts to disrupt supply chains and protect Kansas families.

THC Technical Language Update

The bill also includes technical clarifications to the language governing tetrahydrocannabinols (THC) and marijuana definitions. These adjustments don't change criminal law they just better align statutory language with current federal and state hemp regulations. This reduces ambiguity for both enforcement and regulated industries. This cleanup helps law enforcement focus resources on actual violations rather than interpretive gray areas.

Addition of 7-Hydroxymitragynine (7-OH) to Schedule I

Of particular importance to the KBI is the addition of 7-hydroxymitragynine (7-OH) to Schedule I. 7-OH is a potent opioid receptor agonist derived from the kratom plant but typically sold in highly

concentrated synthetic or semi-synthetic forms. These products far exceed the trace amounts found naturally in traditional kratom leaf.

These products are aggressively marketed and sold in gas stations, smoke shops, convenience stores, and online throughout Kansas. They often are sold in appealing formats such as gummies, shots, tablets, and powders. They are frequently promoted as "natural," safe, or legal alternatives for pain relief, anxiety, or opioid withdrawal. **In reality, concentrated 7-OH and related high-potency products act as powerful opioids.** They carry significant risks of:

- Rapid addiction and tolerance
- Respiratory depression
- Overdose (which can be reversed with naloxone but still endangers lives)
- Severe withdrawal symptoms
- Other adverse effects including anxiety, depression, and gastrointestinal distress

Recent federal seizures of tens of thousands of 7-OH products from Kansas City-area warehouses demonstrate the scale of distribution impacting our state. The Kansas Department of Health and Environment (KDHE) has already issued public warnings about these products. The KBI is seeing increasing encounters with these substances in investigations, often alongside other drugs. Young adults and unsuspecting consumers are particularly vulnerable due to easy access and misleading marketing.

Scheduling 7-OH in Kansas will give law enforcement the necessary authority to remove these dangerous products from the marketplace, prosecute illegal distribution, and deter manufacturers and retailers from endangering Kansans. It sends a clear message that Kansas will not tolerate the unchecked spread of potent opioid-like substances disguised as supplements or "wellness" products.

Conclusion

HB 2765 is a targeted, responsible update that modernizes our controlled substances laws to match current threats. The KBI appreciates the proactive work of the House Health and Human Services Committee and the bill's sponsors on these critical issues. We stand ready to assist with implementation and enforcement.

We respectfully request your favorable recommendation for passage of HB 2765.

#####